McMahon Lance R, Li Jun-Xu, Carroll F Ivy, France Charles P
Department of Pharmacology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.
Psychopharmacology (Berl). 2009 Apr;203(2):411-20. doi: 10.1007/s00213-008-1242-4. Epub 2008 Jul 18.
Some monoamine uptake inhibitors (e.g., cocaine) attenuate the subjective and discriminative stimulus effects of opioid withdrawal.
This study examined a role for dopamine transporters and receptors as targets for drugs to modify the discriminative stimulus effects of opioid withdrawal and further examined a subset of these drugs for their capacity to modify some directly observable and physiologic indices of withdrawal.
Rhesus monkeys receiving 2 mg/kg/day of L: -alpha-acetylmethadol discriminated the opioid antagonist naltrexone (0.0178 mg/kg s.c.).
The naltrexone discriminative stimulus was attenuated not only by the mu agonist morphine but also by the dopamine D(2)-like receptor agonists bromocryptine and quinpirole. In contrast, the naltrexone discriminative stimulus was not consistently modified by the non-selective, D(1)- and D(2)-like agonist apomorphine or by uptake inhibitors with high selectivity for dopamine transporters (GBR 12909, RTI 113, and RTI 177). In the same monkeys, naltrexone dose dependently decreased body temperature, increased breathing frequency, and induced directly observable signs (grimacing, salivation, and unusual posture). Hypothermia, hyperventilation, and signs of withdrawal were significantly attenuated by morphine and not by quinpirole.
Attenuation of opioid withdrawal by D(2)-like receptor agonists that have lower efficacy than dopamine, and not by uptake inhibitors with selectivity for dopamine transporters, suggests that magnitude of receptor stimulation (e.g., efficacy) and selectivity at dopamine receptors are important factors in the modulation of opioid withdrawal. Attenuation of the naltrexone discriminative stimulus by drugs that inhibit both dopamine and serotonin uptake (e.g., cocaine) could result from an inhibitory effect of serotonin on dopamine. The role of dopamine in opioid withdrawal appears to be restricted to subjective (i.e., not somatic) indices [corrected]
一些单胺摄取抑制剂(如可卡因)可减弱阿片类药物戒断的主观和辨别性刺激效应。
本研究考察了多巴胺转运体和受体作为药物靶点对阿片类药物戒断辨别性刺激效应的调节作用,并进一步考察了这些药物中的一部分对一些直接可观察到的戒断生理指标的调节能力。
接受2mg/kg/天左旋-α-乙酰美沙多的恒河猴能够辨别阿片类拮抗剂纳曲酮(0.0178mg/kg皮下注射)。
纳曲酮的辨别性刺激不仅被μ激动剂吗啡减弱,还被多巴胺D(2)样受体激动剂溴隐亭和喹吡罗减弱。相比之下,非选择性的D(1)和D(2)样激动剂阿扑吗啡或对多巴胺转运体具有高选择性的摄取抑制剂(GBR 12909、RTI 113和RTI 177)并未持续改变纳曲酮的辨别性刺激。在同一批猴子中,纳曲酮剂量依赖性地降低体温、增加呼吸频率并引发直接可观察到的体征(鬼脸、流涎和异常姿势)。体温过低、通气过度和戒断体征被吗啡显著减弱,但未被喹吡罗减弱。
效力低于多巴胺的D(2)样受体激动剂而非对多巴胺转运体具有选择性的摄取抑制剂可减弱阿片类药物戒断,这表明受体刺激的强度(如效力)和对多巴胺受体的选择性是调节阿片类药物戒断的重要因素。抑制多巴胺和5-羟色胺摄取的药物(如可卡因)减弱纳曲酮辨别性刺激可能是由于5-羟色胺对多巴胺的抑制作用。多巴胺在阿片类药物戒断中的作用似乎仅限于主观指标(即非躯体指标)[已修正]